The subject of the contract includes 12 parts:

Part 1- Cetuximab

Part 2- Panitumuma

Part 3 - Afatinib

Part 4 - Ribocyclib

Part 5- Trastuzumab emtansine

Part 6- Ibrutinib

Part 7- Carfilzomib

Part 8- Natalizumab

Part 9- Ocrelizumab

Part No. 10- Cladribine

Part No. 11- Ofatumumab

Part No. 12- Immunoglobulins

Cetuximab

Cladribine

Ofatumumab

immunoglobulins

Panitumuma

Afatinib

Ribocyclib

Trastuzumab emtansin

Ibrutynib

Karfilzomib

natalizumab

Okrelizumab